Abstract: A rail flaw detector is configured for locating flaws in rails of a railroad track and for use with a vehicle travelling on the railroad track. The detector includes at least one signal applicator configured for applying ultrasonic signals to the rail and for receiving return signals; a mechanical subsystem connected to the applicator and to the vehicle and configured for maintaining the at least one signal applicator in operational position on the track. A human-machine interface is connected to the at least one signal applicator, is configured to control the detector and to monitor sensed rail condition. In one embodiment, the human-machine interface includes a schematic display of the rail being monitored and at least one touch screen control for controlling the mechanical subsystem and the at least one signal applicator.

Abstract: A rail flaw detector is configured for locating flaws in rails of a railroad track and for use with a vehicle travelling on the railroad track. The detector includes at least one signal applicator configured for applying ultrasonic signals to the rail and for receiving return signals; a mechanical subsystem connected to the applicator and to the vehicle and configured for maintaining the at least one signal applicator in operational position on the track. A human-machine interface is connected to the at least one signal applicator, is configured to control the detector and to monitor sensed rail condition. In one embodiment, the human-machine interface includes a schematic display of the rail being monitored and at least one touch screen control for controlling the mechanical subsystem and the at least one signal applicator.

Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.

Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Abstract: A reference electrode, optionally in combination with a measuring electrode to form a combination electrode, is disclosed in which the salt bridge comprises anionic and cationic ion exchange polymer. This polymer may be a diaphragm forming the liquid junction structure of the reference electrode. Polymer is preferably a mixture of anionic and cationic ion exchange polymer which may be either water insoluble or water soluble and is preferably converted to a form which binds equitransferent ions. When the polymer is substantially insoluble, a water-soluble thickener polymer may be incorporated in the polymer composition. Methods of measuring pH using the electrodes of the invention are also disclosed, particularly in high purity deionized water.

Abstract: A device and method for remote control of a radio or television transmitting station located separate from a control studio and being capable of (i) monitoring preset conditions, (ii) activating notification channels for communication of monitored conditions (iii) responding to commands given remote from the device for initiating remedial or other appropriate actions. The method and device involve use of a microprocessor for locating at the transmitter station and for providing a plurality of input and output ports, means for storing preset conditions and comparing such conditions with status and metering data received at the input ports, and including a memory bank for storing separate action signals for initiating corrective action and for developing stored coded voice signals useful as part of voice synthesis. Alarm notification is provided by voice synthesized and transmitted over telephone lines which enable contact with the remote control device over any public telephone.

Abstract: Chaser for cutting threads on a work piece, the chaser having thread cutting formations with crests and roots, one flank of each of said formations being relieved at a first angle from the region of the crest toward the root and being relieved at a greater angle in the region adjacent the root of the formation. The chasers may be provided in sets with odd numbered chasers being mirror images of the even numbered chasers.